Dai ichi Life Insurance Company Ltd Has $3.06 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Dai ichi Life Insurance Company Ltd lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 29.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,057 shares of the company’s stock after selling 2,586 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in IDEXX Laboratories were worth $3,060,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Mirabella Financial Services LLP boosted its holdings in shares of IDEXX Laboratories by 74.9% during the third quarter. Mirabella Financial Services LLP now owns 23,356 shares of the company’s stock worth $11,800,000 after acquiring an additional 9,999 shares during the period. Brown Brothers Harriman & Co. boosted its stake in IDEXX Laboratories by 4.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 743 shares of the company’s stock valued at $375,000 after purchasing an additional 31 shares during the period. Harvest Fund Management Co. Ltd boosted its stake in IDEXX Laboratories by 43.7% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 3,791 shares of the company’s stock valued at $1,915,000 after purchasing an additional 1,153 shares during the period. Davis R M Inc. grew its holdings in IDEXX Laboratories by 0.8% in the 3rd quarter. Davis R M Inc. now owns 103,378 shares of the company’s stock valued at $52,229,000 after buying an additional 793 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its position in IDEXX Laboratories by 10.1% during the 3rd quarter. Daiwa Securities Group Inc. now owns 16,462 shares of the company’s stock worth $8,316,000 after buying an additional 1,510 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Piper Sandler restated a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Barclays decreased their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Stifel Nicolaus reduced their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $552.38.

IDEXX Laboratories Stock Down 2.6 %

Shares of IDXX opened at $417.32 on Wednesday. The firm has a 50 day simple moving average of $457.31 and a two-hundred day simple moving average of $479.47. The company has a market cap of $34.17 billion, a P/E ratio of 40.24, a P/E/G ratio of 3.74 and a beta of 1.36. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter in the previous year, the firm earned $2.53 EPS. IDEXX Laboratories’s revenue was up 6.6% on a year-over-year basis. Research analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.